Year |
Citation |
Score |
2023 |
McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, Wyse RK, Stott SRW. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. Journal of Parkinson's Disease. 13: 427-439. PMID 37302040 DOI: 10.3233/JPD-239901 |
0.353 |
|
2022 |
Frasier M, Fiske BK, Sherer TB. Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience. 14: 1064057. PMID 36533178 DOI: 10.3389/fnagi.2022.1064057 |
0.38 |
|
2021 |
Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, et al. Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders. PMID 34561166 DOI: 10.1016/j.parkreldis.2021.09.006 |
0.372 |
|
2021 |
Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Cookson M, Das S, Van Deerlin V, ... ... Fiske B, et al. Genome-wide association studies of LRRK2 modifiers of Parkinson's disease. Annals of Neurology. PMID 33938021 DOI: 10.1002/ana.26094 |
0.346 |
|
2020 |
Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Jama Neurology. PMID 33315105 DOI: 10.1001/jamaneurol.2020.4725 |
0.354 |
|
2020 |
Grenn FP, Kim JJ, Makarious MB, Iwaki H, Illarionova A, Brolin K, Kluss JH, Schumacher-Schuh AF, Leonard H, Faghri F, Billingsley K, Krohn L, Hall A, Diez-Fairen M, Periñán MT, ... ... Fiske BK, et al. The Parkinson's Disease Genome-Wide Association Study Locus Browser. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32864809 DOI: 10.1002/Mds.28197 |
0.441 |
|
2020 |
Padmanabhan S, Fiske BK, Baptista MAS. The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells. 9. PMID 32796584 DOI: 10.3390/cells9081878 |
0.463 |
|
2020 |
Barker RA, Bjorklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells A, Fiandaca MS, Stoessl AJ, Eidelberg D, ... ... Fiske B, et al. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease. PMID 32508331 DOI: 10.3233/Jpd-202004 |
0.454 |
|
2020 |
Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, Estrada AA, Fell MJ, Fiske BK, Fuji RN, Galatsis P, Henry AG, Hill S, Hirst W, Houle C, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine. 12. PMID 32321864 DOI: 10.1126/Scitranslmed.Aav0820 |
0.369 |
|
2019 |
Padmanabhan S, Polinski NK, Menalled LB, Baptista MAS, Fiske BK. The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin. Biomolecules. 9. PMID 31344817 DOI: 10.3390/biom9080296 |
0.378 |
|
2019 |
Fiske B. Keys to success for foundation: industry clinical development collaborations Cell and Gene Therapy Insights. 5: 1391-1397. DOI: 10.18609/cgti.2019.145 |
0.216 |
|
2016 |
Sherer TB, Frasier MA, Langston JW, Fiske BK. Parkinson's disease is ready for precision medicine. Personalized Medicine. 13: 405-407. PMID 29767601 DOI: 10.2217/pme-2016-0052 |
0.425 |
|
2016 |
Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 5. PMID 26824392 DOI: 10.7554/Elife.12813 |
0.441 |
|
2016 |
Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, et al. Author response: Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases Elife. DOI: 10.7554/Elife.12813.023 |
0.425 |
|
2016 |
Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MAS, Fiske BK, Fell MJ, Morrow JA, Reith AD, et al. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases Elife. 5. DOI: 10.7554/eLife.12813.001 |
0.3 |
|
2015 |
Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine. 7: 273ra15. PMID 25653221 DOI: 10.1126/Scitranslmed.Aaa3634 |
0.384 |
|
2014 |
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, ... ... Fiske B, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics. 46: 989-93. PMID 25064009 DOI: 10.1038/Ng.3043 |
0.394 |
|
2014 |
Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, ... ... Fiske BK, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiology of Disease. 70: 190-203. PMID 24969022 DOI: 10.1016/j.nbd.2014.06.009 |
0.456 |
|
2014 |
Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, ... ... Fiske B, et al. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging. 35: 266.e5-14. PMID 23962496 DOI: 10.1016/J.Neurobiolaging.2013.07.013 |
0.41 |
|
2013 |
Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. Plos One. 8: e80705. PMID 24244710 DOI: 10.1371/journal.pone.0080705 |
0.403 |
|
2013 |
Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Disease Models & Mechanisms. 6: 1316-24. PMID 24046356 DOI: 10.1242/dmm.011940 |
0.436 |
|
2013 |
Heckman MG, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, ... ... Fiske B, et al. Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1740-4. PMID 23913756 DOI: 10.1002/Mds.25600 |
0.455 |
|
2011 |
Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, ... ... Fiske B, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. The Lancet. Neurology. 10: 898-908. PMID 21885347 DOI: 10.1016/S1474-4422(11)70175-2 |
0.47 |
|
2009 |
Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 731-7. PMID 19133662 DOI: 10.1002/Mds.22446 |
0.425 |
|
2008 |
Fiske BK, Frasier MA, Sherer TB. Special focus section: gene therapy for Parkinson's disease. Experimental Neurology. 209: 28-9. PMID 17980867 DOI: 10.1016/j.expneurol.2007.09.006 |
0.401 |
|
2006 |
Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. The Lancet. Neurology. 5: 917-23. PMID 17052658 DOI: 10.1016/S1474-4422(06)70579-8 |
0.397 |
|
2006 |
Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 136-41. PMID 16470786 DOI: 10.1002/mds.20861 |
0.455 |
|
2004 |
Fiske B. The sexual brain. Nature Neuroscience. 7: 1029-1029. PMID 15452572 DOI: 10.1038/Nn1004-1029 |
0.301 |
|
2003 |
Fiske B. The master clock becomes a servant Nature Neuroscience. 6: 108-108. PMID 12555102 DOI: 10.1038/Nn0203-108 |
0.346 |
|
2002 |
Fiske B. Wnt signals lead cells down the caudal path. Nature Neuroscience. 5: 510-510. PMID 12037518 DOI: 10.1038/Nn0602-510 |
0.311 |
|
2002 |
Angelastro JM, Ryu EJ, Törõcsik B, Fiske BK, Greene LA. Blue-white selection step enhances the yield of SAGE concatemers. Biotechniques. 32: 484, 486. PMID 11911650 DOI: 10.2144/02323Bm02 |
0.431 |
|
2002 |
Fiske B. Putative chemoreceptors get close to arteries Nature Neuroscience. 5: 396-396. DOI: 10.1038/Nn0502-396 |
0.293 |
|
2001 |
Fiske BK, Brunjes PC. NMDA receptor regulation of cell death in the rat olfactory bulb. Journal of Neurobiology. 47: 223-32. PMID 11333403 DOI: 10.1002/neu.1029 |
0.605 |
|
2001 |
Fiske BK, Brunjes PC. Cell death in the developing and sensory-deprived rat olfactory bulb. The Journal of Comparative Neurology. 431: 311-9. PMID 11170007 DOI: 10.1002/1096-9861(20010312)431:3<311::AID-CNE1072>3.0.CO;2-7 |
0.616 |
|
2000 |
Fiske BK, Brunjes PC. Microglial activation in the developing rat olfactory bulb. Neuroscience. 96: 807-15. PMID 10727798 DOI: 10.1016/S0306-4522(99)00601-6 |
0.611 |
|
1999 |
Fiske BK, Brunjes PC. Ribosomal RNA expression in the developing rat olfactory bulb. Brain Research. Developmental Brain Research. 113: 55-60. PMID 10064874 DOI: 10.1016/S0165-3806(98)00189-8 |
0.604 |
|
Show low-probability matches. |